1 / 15

Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power

Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power. PRIMO: Observational Study in 7924 Patients. Genetics: PCSK9. PCSK9 Monoclonal Antibody vs Placebo on LDL-C Levels. Dosing and Administration. LAPLACE-TIMI 57: AMG 145 Q2W Dose Response -- Change in LDL-C From Baseline.

billy
Download Presentation

Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Modulating PCSK9 and the LDL Receptor: Tipping the Balance of Power

  2. PRIMO: Observational Study in 7924 Patients

  3. Genetics: PCSK9

  4. PCSK9 Monoclonal Antibody vs Placebo on LDL-C Levels

  5. Dosing and Administration

  6. LAPLACE-TIMI 57: AMG 145 Q2W Dose Response -- Change in LDL-C From Baseline

  7. Cholesterol Treatment Trialists Collaboration (N = 170,000)

  8. Lipid-Lowering Goals: Back to Nature?

  9. Impact of LDL-C on Plaque Progression

  10. Global Assessment of Plaque Regression With a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV)

  11. PCSK9: Barriers

  12. Large Unmet Medical Need

  13. Thank you for participatingin this activity.To proceed to the CME posttest, click the Earn CME Credit link on this page.

More Related